Survival from breast cancer in women with a BRCA2 mutation by treatment

DG Evans; KA Phillips; RL Milne; R Fruscio; C Cybulski; J Gronwald; J Lubinski; T Huzarski; Z Hyder; C Forde; K Metcalfe; L Senter; J Weitzel; N Tung; D Zakalik; M Ekholm; P Sun; SA Narod; M Blasinska-Morawiec; M Chosia; K Drosik; S Gozdecka-Grodecka; S Gozdz; E Grzybowska; A Jeziorski; A Karczewska; R Kordek; A Synowiec; B Kozak-Klonowska; K Lamperska; D Lange; A Mackiewicz; JW Mitus; S Niepsuj; O Oszurek; K Gugala; Z Morawiec; T Mierzwa; M Posmyk; J Rys; C Szczylik; M Ucinski; K Urbanski; B Wasko; P Wandzel; M Friedlander; SA McLachlan; S Nesci; S Picken; S O’Connor; L Stanhope; A Eisen; K Sweet; R Kim; W Foulkes; P Moller; S Neuhausen; C Cullinane; C Eng; P Ainsworth; F Couch; C Singer; B Karlan; W McKinnon; M Wood

Journal article

Survival from breast cancer in women with a BRCA2 mutation by treatment

DG Evans, KA Phillips, RL Milne, R Fruscio, C Cybulski, J Gronwald, J Lubinski, T Huzarski, Z Hyder, C Forde, K Metcalfe, L Senter, J Weitzel, N Tung, D Zakalik, M Ekholm, P Sun, SA Narod, M Blasinska-Morawiec, M Chosia Show all

British Journal of Cancer | Published : 2021

DOI: 10.1038/s41416-020-01164-1

Download PDF

Abstract

Background: The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation. Methods: We identified 664 women with stage I–III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted ..

View full abstract

University of Melbourne Researchers

Kelly Phillips Author

Roger Milne Author

Sue-Anne McLachlan Author

Related Projects (5)

THE KATHLEEN CUNINGHAM FOUNDATION CONSORTIUM FOR RESEARCH INTO FAMILIAL BREAST CANCER (KCONFAB)

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

TRANSLATING EVIDENCE INTO PRACTICE: OPTIMISING AND FACILITATING PREVENTION AND SCREENING IN WOMEN WITH A STRONG FAMILY HISTORY OF BREAST CANCER

Optimization models and methods are widely used in decision problems. Incorporating parameter uncertainty is important in constructing repre..

PRECISION PREVENTION – FROM PRIORITY TO REALITY

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

This work was supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia (809195, 1100868), the Australian National Breast Cancer Foundation (IF 17), the National Health and Medical Research Council (454508, 288704 and 145684), the National Institute of Health USA (1RO1CA159868), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia and the Cancer Foundation of Western Australia. K.A.P. is an Australian National Breast Cancer Foundation Fellow (PRAC17-004). The work is supported by the Peter Gilgan Center for Research on Women's Cancers and the Canadian Institute of Health Research (FDN 154275). D.G.E. is supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007).